Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg se

StephenW

回复 把握当下 的帖子

"fold" - 倍 e.g. 3-fold increase = 3 X
数量级 = "order of magnitude"

非常混乱

把握当下

StephenW 发表于 2012-3-12 20:33
回复 把握当下 的帖子

"fold" - 倍 e.g. 3-fold increase = 3 X

mess indeed
maybe ask someone who actually caculates these numbers
i think i might be right

StephenW

回复 把握当下 的帖子

StephenW

回复 把握当下 的帖子

[This is another version of the abstract - different numbers???]


ADD-ON OF PEG-INTERFERON TO A STABLE NUCLEOS(T)IDE REGIMEN LEADS TO LOSS OF HBS-AG IN PATIENTS WITH CHRONIC HEPATITIS B

J.M. Kittner1*, M.F. Sprinzl2, A. Grambihler1, A. Weinmann1, P.R. Galle1, M. Schuchmann1
11st Medical Dept., University Hospital Mainz, Mainz, 2Institute for Virology, Technical University of Munich, Munich, Germany. ****@****


Objective: Suppression of HBV viral load by nucleos(t)ide therapy effectively reduces disease progression but requires long-term medication. Preferably, self-contained immunological control represented by HBs-Ag seroconversion should be achieved. It is of interest to know whether the addition of peg-interferon to a stable nucleos(t)ide therapy will reduce quantitative HBs-Ag which may be followed by HBs-Ag seroconversion.
Methods: We observed HBs-Ag levels of 12 patients who received additional peg-interferon-alfa2a as an individualized therapy. 9 patients were male, mean age was 44 (range 25-60) years. 3 patients were HBe-antigen positive. Current treatment comprised lamivudine (1pt.), lamivudine plus adefovir (2pts.), entecavir (7pts.), or entecavir plus tenofovir (2pts.). Mean baseline HBs-Ag accounted for 4,695 (range 16-15,120) IU/ml. HBV viral load was below limit of detection ( 6 months.
Results: During add-on therapy, in 2 patients a continuous decline of quantitative HBsAg by -2,6log10 and -3,66 log10 was observed at week 32 and 36, respectively. The decline became detectable from week 8 and 16 on, resp. The first patient was HBe-Ag negative, genotype D, with cirrhosis grade Child-Pugh A, had a low initial HBsAg level of 16 U/l which dropped to 0.04 U/l. HBV-DNA had previously been non-detectable during therapy with entecavir for 27 months.
The second patient was HBe-positive, genotype A, F3 fibrosis (Desmet), and HBV-DNA had been non-detectable for 10 months with entecavir plus tenofovir. Despite a non-response to peg-interferon monotherapy in the past, she now experienced an HBe-antigen seroconversion at week 24. HBs-Ag dropped to 0.54 U/l, and anti-HBs became detectable in week 32.
In the remaining 10 patients quantitative HBsAg declined only by -0.01 to -0.25 log10 (mean 0.09 log10) after 8-24 (mean 16.4) weeks of combination therapy, and therefore interferon was stopped.
No unexpected side effects were observed in combination therapy.
Conclusion: HBs-Ag loss during oral antiviral therapy is rare, even more in HBe-negative patients. Here, we show that the add-on of peg-interferon induced HBsAg loss in 2 of 12 patients (one HBe-Ag negative) and even led to HBs-Ag seroconversion in one patient. This concept merits to be proven in a larger trial.                            

把握当下

in 2 patients a continuous decline of quantitative HBsAg by -2,6log10 and -3,66 log10 was observed at week 32 and 36, respectively

had a low initial HBsAg level of 16 U/l which dropped to 0.04 U/l

2.6=lg(16)-lg(0.04) ,so....

StephenW

回复 把握当下 的帖子

log(16) = 1.2
log(0.04) = -1.39
log(16) - log(0.04) = 2.6   != -2.6  and != -2.6log(10)
but
log(0.04/16) = -2.6

三国杀

你们俩真牛
那个是数量级的意思

核苷联合干扰素其实在国内也有研究的，不过，联合的核苷都是拉米或者阿德

没有用替诺福韦

StephenW

回复 三国杀 的帖子

"核苷联合干扰素其实在国内也有研究的，不过，联合的核苷都是拉米或者阿德
没有用替诺福韦" - 同意。新方法似乎建议使用一种强效抗病毒药物抑制HBVDNA
至“检测不到”一段时间，然后添加干扰素.

scilab

联合后，效果怎样呢？ 哪天我也试试。

StephenW

回复 scilab 的帖子

意大利的朋友建议说治愈率可以是>80％（没有证据）